Date: 2014-11-20
Type of information: Opening of new premises
Compound:
Company: Amgen (USA - CA)
Therapeutic area:
Type agreement: opening of new biomanufacturing facilities
Action mechanism:
Disease:
Details: * On November 20, 2014, Amgen has completed construction of its first Next-Generation Biomanufacturing facility, located in Singapore. Built in less than two years, the Next-Generation Biomanufacturing facility was completed in half the time required for conventional biomanufacturing plants. It uses single-use bioreactors, disposable plastic containers, continuous purification processing and real-time quality analysis. This flexible, modular design can be replicated in future facilities, enabling higher production and greater accessibility to patients around the world. The Next-Generation Biomanufacturing facility is expected to have the same annual output as a conventional facility but in a single building that will use less energy and water and have lower solid waste and emission levels -- all in line with Singapore\'s commitment to sustainable and innovative economic development. Amgen also announced it will continue building at its Tuas site in Singapore and will soon break ground on another facility where it will make carfilzomib, the active ingredient for Kyprolis®.
Financial terms:
Latest news:
